

## Electronic Supplementary information

to accompany the manuscript entitled:

### Synthesis and *in vivo* evaluation of a radiofluorinated ketone body derivative

Stephanie J. Mattingly,<sup>a</sup> Melinda Wuest,<sup>a,e</sup> Eugene J. Fine,<sup>b</sup> Ralf Schirmacher,<sup>a,c</sup> Frank Wuesta,<sup>c,d,e\*</sup>

<sup>a</sup>Department of Oncology, University of Alberta, Edmonton, Canada

<sup>b</sup>Department of Nuclear Medicine, Albert Einstein College of Medicine, NY, NY, USA

<sup>c</sup>Department of Chemistry, University of Alberta, Edmonton, Canada

<sup>d</sup>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada


<sup>e</sup>Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Canada

## Contents


<b>Figure S1</b> PET images in normal BALB/c mice .....	2
<b>Figure S2</b> Time-activity curves of select organs in normal BALB/c mice .....	3
<b>Figure S3</b> PET images of MDA-MB231 xenograft mice with nitrile intermediates.....	4
<b>Figure S4</b> Changes in blood glucose and blood ketone body concentrations.....	5
Preparation of compound <b>3a</b> .....	5
Preparation of compound <b>3b</b> .....	5
Preparation of compound <b>3c</b> .....	5
Preparation of compound <b>4</b> .....	5
Preparation of nitrile reference standard FCH <sub>2</sub> CHOHCH <sub>2</sub> CN .....	6
Notes: nitrilase conversion step .....	6
NMR spectra: compound <b>3a</b> .....	1
NMR spectra: compound <b>3b</b> .....	3
NMR spectra: compound <b>3c</b> .....	5
NMR spectra: compound <b>4</b> .....	7
NMR spectra: nitrile reference standard FCH <sub>2</sub> CHOHCH <sub>2</sub> CN .....	8

**[<sup>18</sup>F]FBHB**


*normal BALB/c mouse*



**(R)-[<sup>18</sup>F]F3HB**




**Figure S1** PET images in normal BALB/c mice post tail vein injection of [<sup>18</sup>F]FBHB (upper) and (R)-[<sup>18</sup>F]F3HB (lower) over 60 min. MIP, maximum intensity projection; SUV, standard uptake value.




**Figure S2** Time-activity curves of select organs in normal BALB/c mice post tail vein injection of  $[^{18}\text{F}]$ FBHB or  $(R)$ - $[^{18}\text{F}]$ F3HB over 60 min.

**(R)-[<sup>18</sup>F]-nitrile, [<sup>18</sup>F]19**

**(S)-[<sup>18</sup>F]-nitrile, [<sup>18</sup>F]16**




**Figure S3** PET images of MDA-MB231 xenograft mice with nitrile intermediates compounds [<sup>18</sup>F]19 ((R)-[<sup>18</sup>F]-nitrile) or [<sup>18</sup>F]16 ((S)-[<sup>18</sup>F]-nitrile) 1h post injection (*upper*); corresponding time-activity curves of tumor versus muscle uptake (*lower*)




**Figure S4** Changes in blood glucose and blood ketone body concentrations prior to and post a 24 h fast

### Preparation of compound **3a**




Compound **3a** was prepared according to Li et al.<sup>1</sup> To a solution of methyl 3-oxobutanoate (0.538 g, 4.63 mmol) in benzene (23 mL) was added N-bromosuccinimide (1.016 g, 5.71 mmol) and catalytic AIBN (0.316 g of a 12% solution in acetone, 0.2316 mmol). The mixture was stirred at rt for 24h. The solvents were removed by rotary evaporation. The crude product was purified by silica column chromatography (7:3 CH<sub>2</sub>Cl<sub>2</sub>:hexanes isocratic) and the purified product was isolated as a yellow oil (0.5634 g, 90.3%) (*R*<sub>f</sub> = 0.59 1:1 hexanes/EtOAc, KMnO<sub>4</sub> stain). The spectral properties differed slightly from Li et al. but were in agreement with the same compound prepared by Khan et al.<sup>2</sup> <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ = 4.78 (s, 1H), 3.85 (s, 3H), 2.46 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ = 196.2 (C), 165.6 (C), 53.8 (CH), 48.6 (CH<sub>3</sub>), 26.4 (CH<sub>3</sub>). LCMS: *m/z* [M]<sup>+</sup> calcd for C<sub>5</sub>H<sub>8</sub>BrO<sub>3</sub>: 194.9656, 196.9636; found: 195.0, 197.0.

### Preparation of compound **3b**




Compound **3b** was prepared using the same methodology as for **3a**. Spectral properties were in agreement with the compound as prepared by Wu et al.<sup>3</sup> <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ = 4.76 (s, 1H), 4.29 (q, *J* = 6.40 Hz, 2H), 2.45 (s, 3H), 1.32 (t, *J* = 7.15, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ = 196.4 (C), 165.1 (C), 63.2 (CH<sub>2</sub>), 49.1 (CH), 26.4 (CH<sub>3</sub>), 13.9 (CH<sub>3</sub>).

## Preparation of compound **3c**




Compound **3c** was prepared using the same methodology as for **3a**. Spectral properties were in agreement with the same compound prepared by Khan et al.<sup>2</sup> <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  = 4.68 (s, 1H), 2.42 (s, 3H), 1.50 (s, 9H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  = 196.7 (C), 164.0 (C), 84.5 (C), 50.7 (CH), 27.7 (CH<sub>3</sub>), 26.3 (CH<sub>3</sub>).

## Preparation of compound **4**



Compound **4** was prepared according to Coats et al.<sup>4</sup> To *tert*-butyl acetoacetate (0.477 g, 3.01 mmol) in CH<sub>3</sub>CN (15 mL) was added Koser's reagent ([hydroxy(tosyloxy)iodo]benzene) (1.42 g, 3.62 mmol). The slurry was heated to 70 °C until a colorless homogenous solution was obtained (<2h). The crude product was purified by silica column chromatography, gradient elution 1:0 to 7:3 hexanes:EtOAc ( $R_f$  = 0.31 4:1 hexanes/EtOAc). Compound **4** was isolated as a white solid (0.7418 g, 99%). Spectral properties compare well with those reported for the methyl ester derivative by Yamamoto et al.<sup>5</sup> <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.84 (d,  $J$  = 8.28 Hz, 2H), 7.37 (d,  $J$  = 8.66 Hz, 2H), 5.31 (s, 1H), 2.46 (s, 3H), 2.29 (s, 3H), 1.40 (s, 9H).

## Preparation of nitrile reference standard FCH<sub>2</sub>CHOHCH<sub>2</sub>CN





Nitrile reference standard FCH<sub>2</sub>CHOHCH<sub>2</sub>CN was prepared according to Liu et al.<sup>6</sup> CAUTION: HCN (b.p. 25.6 °C) and epifluorohydrin (b.p. 85-86 °C) are toxic. H<sub>2</sub>SO<sub>4</sub> (0.967 g, 9.86 mmol) was dissolved in water (33 mL) and chilled in an ice bath. To this solution was added epifluorohydrin (0.250 g, 3.29 mmol) followed by KCN (1.712 g, 26.3 mmol). The reaction mixture was allowed to gradually come to rt and was stirred for 16 h. The reaction mixture was extracted with EtOAc (3x30 mL), washed with saturated aqueous NaHCO<sub>3</sub> (20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent evaporated by rotary evaporation. The crude product was purified by silica column chromatography eluting with hexanes/EtOAc ( $R_f$  = 0.28 1:1 hexanes/EtOAc, KMnO<sub>4</sub> stain). The solvents were evaporated yielding FCH<sub>2</sub>CHOHCH<sub>2</sub>CN (0.3097 g, 91.3%) as a bright yellow oil. <sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>):  $\delta$  = -230.94 (td,  $J$  = 47.0, 17.8 Hz). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  = 4.47 (dd, <sup>2</sup> $J_{H-F}$  = 47.1 Hz, <sup>3</sup> $J_{H-H}$  = 4.89 Hz, 2H), 4.17-4.27 (m, 1H), 3.08 (brs, 1H), 2.71-2.61 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  = 116.8 (C), 85.6 (d, <sup>1</sup> $J_{C-F}$  = 172.6 Hz, CH<sub>2</sub>F), 66.1 (d, <sup>2</sup> $J_{C-F}$  = 22.1 Hz, CH), 21.7 (d, <sup>3</sup> $J_{C-F}$  = 7.7 Hz, CH<sub>2</sub>).

## Notes: nitrilase conversion step

The enzymatic conversion step resulted in lower yields at temperatures above 30 °C and at pH below 9. Yields improved when PBS buffer was added; however, in this instance the presence of buffer salts hindered QMA cartridge capture of the final product acids. Note that for HPLC-based verifications of acids [<sup>18</sup>F]FBHB and (R)-[<sup>18</sup>F]F3HB, elution times vary depending on solvent pH and ionic strength (i.e. the presence of buffer salts).


NMR spectra: compound **3a**










NMR spectra: compound **3b**






NMR spectra: compound 3c









NMR spectra: compound 4



NMR spectra: nitrile reference standard FCH<sub>2</sub>CHOHCH<sub>2</sub>CN









1. Z. Li, M. Khaliq, Z. Zhou, C. B. Post, R. J. Kuhn and M. Cushman, *J. Med. Chem.*, 2008, **51**, 4660-4671.
2. A. T. Khan, M. A. Ali, P. Goswami and L. H. Choudhury, *J. Org. Chem.*, 2006, **71**, 8961-8963.
3. L. Wu and Z. Yin, *European Journal of Inorganic Chemistry*, 2013, **2013**, 6156-6163.
4. S. J. Coats and H. H. Wasserman, *Tetrahedron Lett.*, 1995, **36**, 7735-7738.
5. Y. Yamamoto, Y. Kawano, P. H. Toy and H. Togo, *Tetrahedron*, 2007, **63**, 4680-4687.
6. Y. Liu, C. Hazzard, A. S. Eustaquio, K. A. Reynolds and B. S. Moore, *J. Am. Chem. Soc.*, 2009, **131**, 10376-10377.